Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for ONCSQ.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
January 31, 2023 -6.611M
October 31, 2022 -6.127M
July 31, 2022 -6.916M
April 30, 2022 -5.341M
January 31, 2022 -10.01M
October 31, 2021 -9.868M
July 31, 2021 -8.407M
April 30, 2021 -12.80M
January 31, 2021 -10.85M
October 31, 2020 -9.739M
July 31, 2020 -9.362M
April 30, 2020 -8.212M
January 31, 2020 -7.441M
October 31, 2019 -8.131M
July 31, 2019 -8.093M
April 30, 2019 -7.684M
January 31, 2019 -6.449M
October 31, 2018 -6.778M
July 31, 2018 -6.222M
April 30, 2018 -5.786M
January 31, 2018 -6.134M
October 31, 2017 -5.080M
July 31, 2017 -4.628M
April 30, 2017 -4.475M
January 31, 2017 -3.813M
Date Value
October 31, 2016 -4.425M
July 31, 2016 -4.068M
April 30, 2016 -4.731M
January 31, 2016 -4.357M
October 31, 2015 -4.658M
July 31, 2015 -5.223M
April 30, 2015 -5.062M
January 31, 2015 -3.937M
October 31, 2014 -3.430M
July 31, 2014 -2.712M
April 30, 2014 -2.438M
January 31, 2014 -1.775M
October 31, 2013 -2.055M
July 31, 2013 -1.301M
April 30, 2013 -1.639M
January 31, 2013 -1.376M
October 31, 2012 -1.217M
July 31, 2012 -1.397M
April 30, 2012 -0.941M
January 31, 2012 -0.95M
October 31, 2011 -0.9312M
July 31, 2011 -1.042M
April 30, 2011 -0.2512M
January 31, 2011 -0.0115M
October 31, 2010 -0.0045M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 100.78M
Alnylam Pharmaceuticals, Inc. 326.72M
Anika Therapeutics, Inc. -0.684M
Savara, Inc. -29.75M
Vericel Corp. 16.19M